Lixte Biotechnology faces Nasdaq delisting over equity ...
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) received a Nasdaq non-compliance notice for falling below the $2.5M stockholders' equity requirement. It has 45 days to submit a compliance plan, with a possible 180-day extension. The company is exploring options to regain compliance, while its shares continue trading. Recent changes include a shift to equity-based director compensation and a clinical trial agreement with the Netherlands Cancer Institute for cancer drug LB-100.
Reference News
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) received a Nasdaq non-compliance notice for falling below the $2.5M stockholders' equity requirement. It has 45 days to submit a compliance plan, with a possible 180-day extension. The company is exploring options to regain compliance, while its shares continue trading. Recent changes include a shift to equity-based director compensation and a clinical trial agreement with the Netherlands Cancer Institute for cancer drug LB-100.